Hims & Hers Health, Inc. (NYSE:HIMS) Given Average Rating of "Hold" by Brokerages

Shares of Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) have earned an average rating of "Hold" from the thirteen brokerages that are covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and three have issued a buy rating on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $37.67.

Several research firms have recently issued reports on HIMS. Bank of America lifted their price target on Hims & Hers Health from $22.00 to $26.00 and gave the stock an "underperform" rating in a research report on Tuesday, April 29th. TD Cowen lowered Hims & Hers Health from a "buy" rating to a "hold" rating and lowered their price target for the stock from $44.00 to $30.00 in a research report on Tuesday, April 29th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Hims & Hers Health in a research report on Wednesday, May 7th. Piper Sandler reaffirmed a "neutral" rating and issued a $39.00 price target (up previously from $35.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Finally, Canaccord Genuity Group lifted their price target on Hims & Hers Health from $38.00 to $68.00 and gave the stock a "buy" rating in a research report on Wednesday, February 19th.

Hims & Hers Health Trading Down 3.4%

Shares of Hims & Hers Health stock opened at $61.82 on Thursday. The firm has a market capitalization of $13.84 billion, a P/E ratio of 140.50 and a beta of 1.84. The business has a fifty day simple moving average of $34.36 and a two-hundred day simple moving average of $33.16. Hims & Hers Health has a 12 month low of $13.47 and a 12 month high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.12 by $0.08. The business had revenue of $586.01 million during the quarter, compared to analyst estimates of $535.21 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company's revenue for the quarter was up 110.7% on a year-over-year basis. During the same quarter last year, the firm posted $0.05 earnings per share. Analysts predict that Hims & Hers Health will post 0.29 earnings per share for the current year.

Insider Buying and Selling at Hims & Hers Health

In related news, insider Patrick Harrison Carroll sold 23,287 shares of the business's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $34.31, for a total value of $798,976.97. Following the transaction, the insider now directly owns 209,661 shares of the company's stock, valued at approximately $7,193,468.91. The trade was a 10.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Soleil Boughton sold 4,152 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $60.69, for a total value of $251,984.88. Following the completion of the transaction, the insider now directly owns 157,345 shares in the company, valued at approximately $9,549,268.05. This represents a 2.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 563,973 shares of company stock worth $21,951,757 in the last three months. 13.71% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its holdings in Hims & Hers Health by 11.1% in the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock worth $489,817,000 after purchasing an additional 2,020,722 shares in the last quarter. Farallon Capital Management LLC lifted its holdings in Hims & Hers Health by 64,338.5% in the 4th quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock worth $202,556,000 after purchasing an additional 8,364,000 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Hims & Hers Health by 29.0% in the 4th quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company's stock worth $168,079,000 after purchasing an additional 1,562,302 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in shares of Hims & Hers Health by 192.0% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock worth $152,436,000 after acquiring an additional 4,145,305 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Hims & Hers Health by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 4,329,996 shares of the company's stock worth $104,724,000 after acquiring an additional 40,447 shares in the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.